In vivo T-cell depletion with low-dose ATG is effective in reducing cGVHD after peripheral blood stem cell myeloablative sibling transplants in CML: results from a prospective phase II study

Bone Marrow Transplant. 2005 May;35(10):1025-6. doi: 10.1038/sj.bmt.1704940.
No abstract available

Publication types

  • Clinical Trial
  • Clinical Trial, Phase II
  • Letter

MeSH terms

  • Adult
  • Antilymphocyte Serum / therapeutic use*
  • Chronic Disease
  • Graft vs Host Disease / prevention & control*
  • Humans
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy*
  • Lymphocyte Depletion*
  • Middle Aged
  • Peripheral Blood Stem Cell Transplantation*
  • Prospective Studies

Substances

  • Antilymphocyte Serum